ArticleScientific reports2026
Efficacy and safety of ultrasound-guided microwave ablation for primary hyperparathyroidism: a dual-centre study.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
This study aimed to evaluate the efficacy and safety of ultrasound-guided microwave ablation (MWA) for the treatment of primary hyperparathyroidism (PHPT). This study enrolled 46 patients with PHPT from two centers between July 2019 and January 2024. The primary end point was clinical success, defined as the achievement of normal levels of both intact parathyroid hormone (iPTH) and serum calcium at 6 months post-MWA (40/46). Secondary end points were technical success and procedure-related complications, with the former defined as the achievement of complete ablation. The clinical and technical success rate were 87.0% (40/46) and 100.0% (56/56), respectively. Serum iPTH, calcium and phosphorus showed significant improvement within the 6 months post-MWA [iPTH, 156.6 (114.3-241.0) pg/mL vs. 58.3 (49.0-62.4) pg/mL; calcium, 2.70 ± 0.30 mmol/L vs. 2.38 ± 0.11 mmol/L; phosphorus, 0.86 ± 0.19 mmol/L vs. 1.01 ± 0.17 mmol/L, respectively; all, p < 0.01]. The 6-month volume reduction rate (VRR) was 79.0%, and no long-term complications were observed during follow-up. These results suggest that ultrasound-guided MWA is a safe and effective non-surgical alternative for the management of PHPT.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.